News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
217–252
Matches
770
Sources here
20
Companies here
9
Search results Stored financial headlines

Active search

770 matching headlines

Ticker or company: TEKMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Precision Trading with Camtek Ltd. (CAMT) Risk Zones

This article provides an AI-generated analysis for Camtek Ltd. (CAMT), highlighting current market sentiment, risk zones, and various trading strategies. It outlines distinct entry and exit points, target prices, and stop losses for position trading, momentum breakout, and risk hedging, based on near-term, mid-term, …

CAMT main company
Sharemaestro market context Price above Trend Line 52 weeks +100.4% · Next-week setup positive 55.0% CAMT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Alpha Teknova (Nasdaq: TKNO) raises 2026 guidance after Q2 growth

Alpha Teknova (Nasdaq: TKNO) reported strong Q2 2026 financial results, with revenue increasing 18% to $12.2 million and improved profitability metrics. Following this performance, the company raised its 2026 revenue guidance to $45-$47 million and lowered its Free Cash Outflow expectations to less than …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Flotek Industries, Inc. Stock 12‑Month Price Target Raised to $29.58, Implies 5% Upside

The 12-month average price target for Flotek Industries, Inc. (FTK) stock has increased from $26.72 to $29.58, according to 7 analysts. This new target suggests a potential upside of approximately 5% from its August 4th closing price. The consensus analyst rating remains a "Buy," …

FTK main company
Sharemaestro market context Trend signal active 52 weeks +200.6% · Next-week setup negative 44.3% FTK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cytek Biosciences Reports Second Quarter 2026 Financial Results

Cytek Biosciences reported its second-quarter 2026 financial results, with total revenue reaching $48.1 million, a 6% increase year-over-year. The company also announced the launch of new instruments, the Cytek Borealis™ and updated Cytek Aurora™ Evo configurations, and updated its full-year 2026 revenue guidance to …

CTKB main company
Sharemaestro market context Price above Trend Line 52 weeks +13.0% · Next-week setup negative 44.1% CTKB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...

Cytek Biosciences (CTKB) reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong growth in the US and China, particularly from high-end instrument sales and services. Despite this, the company saw a widened GAAP net loss of $12.2 million …

CTKB main company
Sharemaestro market context Price above Trend Line 52 weeks +13.0% · Next-week setup negative 44.1% CTKB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AMETEK (NYSE:AME) Price Target Raised to $285.00 at DA Davidson

DA Davidson has increased its price target for AMETEK (NYSE:AME) to $285.00 from $265.00, maintaining a "buy" rating on the stock, implying an 11.9% upside. This follows AMETEK's strong Q2 2026 earnings report, where the company beat analyst estimates with $2.09 EPS and $2.04 …

AME main company
Sharemaestro market context Trend signal active 52 weeks +37.1% · Next-week setup positive 55.4% AME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Earnings call transcript: Teknova posts record Q2 2026 revenue and raises outlook

Teknova (TKNO) reported record Q2 2026 revenue of $12.2 million and a narrower-than-expected loss of $0.06 per share, leading the company to raise its full-year 2026 revenue guidance to $45-$47 million. Despite the strong financial performance and the launch of an AI-powered custom order …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million

Cytek Biosciences reported its Q2 2026 financial results, showing a 6% year-over-year increase in revenue to $48.1 million. Despite the revenue growth, the company's GAAP net loss widened to $12.2 million, and its GAAP operating loss increased to $11.4 million. The gross margin improved …

CTKB main company
Sharemaestro market context Price above Trend Line 52 weeks +13.0% · Next-week setup negative 44.1% CTKB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Camtek (CAMT) Dips More Than Broader Market: What You Should Know

Camtek (CAMT) closed at $147.60 in the latest trading session, marking a -2.65% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.17%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq depreciated by …

CAMT main company CAMT main company
Sharemaestro market context Price above Trend Line 52 weeks +85.2% · Next-week setup positive 55.2% CAMT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Teknova Reports Second Quarter 2026 Financial Results

Teknova (Nasdaq: TKNO) announced strong financial results for the second quarter of 2026, with total revenue reaching $12.2 million, an 18% increase year-over-year. The company also raised its full-year 2026 revenue guidance to $45-$47 million and introduced its AI-powered Build-Tek™ custom order configurator to …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Teknova Q2 2026 Earnings: Revenue Growth Drives Higher Guidance

Teknova (Nasdaq: TKNO) reported a strong Q2 2026 with revenue up 18% to $12.2 million, narrowing its GAAP diluted EPS loss to $0.06. The company saw broad-based growth across its Lab Essentials and Clinical Solutions segments, leading to improved operating leverage and significantly reduced …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1 million, a 5.6% increase year-over-year, and gross profit rose by 18.7% to $28.3 million. Despite revenue growth, the company posted a net loss of $12.2 million, or $(0.09) diluted EPS, missing analyst expectations of $(0.0867) …

CTKB main company
Sharemaestro market context Price above Trend Line 52 weeks +13.0% · Next-week setup negative 44.1% CTKB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cytek Q2 2026 Earnings: Revenue Rose 6% as Losses Widened

Cytek (Nasdaq: CTKB) reported a 6% increase in Q2 2026 revenue to $48.1 million, driven by instrument growth in the U.S. and China and higher service revenue. However, the company's net losses widened significantly due to a faster increase in operating expenses and weaker …

CTKB main company
Sharemaestro market context Price above Trend Line 52 weeks +13.0% · Next-week setup negative 44.1% CTKB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cytek Biosciences GAAP EPS of -$0.09 in-line, revenue of $48.1M misses by $0.51M

* Cytek Biosciences press release [https://seekingalpha.com/pr/20608750-cytek-biosciences-reports-second-quarter-2026-financial-results] (CTKB [https://seekingalpha.com/symbol/CTKB]): Q2 GAAP EPS of -$0.09 in-line. * Revenue of $48.1M (+5.5% Y/Y) misses by $0.51M. * GAAP gross profit was $28.3 million for the second quarter of 2026, a 19% increase compared to the second quarter …

CTKB main company
Sharemaestro market context Price above Trend Line 52 weeks +13.0% · Next-week setup negative 44.1% CTKB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall

Cytek Biosciences reported a 6% increase in second-quarter 2026 revenue to $48.1 million, driven by strong demand in the U.S. and China, but also announced a wider net loss and negative adjusted EBITDA. Despite raising the low end of its full-year revenue guidance, shares …

CTKB main company
Sharemaestro market context Price above Trend Line 52 weeks +13.0% · Next-week setup negative 44.1% CTKB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AMETEK (NYSE:AME) Price Target Raised to $280.00 at BNP Paribas Exane

BNP Paribas Exane raised AMETEK's price target to $280 from $270, maintaining an "outperform" rating with a potential upside of 9.58%. This follows AMETEK's strong Q2 2026 results, surpassing analyst expectations with EPS of $2.09 and revenue of $2.04 billion, driven by robust performance …

AME main company
Sharemaestro market context Trend signal active 52 weeks +37.1% · Next-week setup positive 55.4% AME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AME Stock Price and Chart — NYSE:AME

This article provides a comprehensive overview of AMETEK, Inc. (AME) stock, including its current price, historical performance, key financial metrics, and latest earnings report. It also features analyst ratings, investment ideas from the TradingView community, and a list of ETFs holding the stock, alongside …

AME main company
Sharemaestro market context Trend signal active 52 weeks +37.1% · Next-week setup positive 55.4% AME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Citigroup Adjusts Price Target on AMETEK to $261 From $257

Citigroup has adjusted its price target for AMETEK (AME) shares to $261, up from the previous $257. This change was published on August 5, 2026, at 11:28 am EDT. The article also lists several other analyst target price adjustments for AMETEK from various financial …

AME main company
Sharemaestro market context Trend signal active 52 weeks +37.1% · Next-week setup positive 55.4% AME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Flotek Industries (NYSE:FTK) Shares Up 29.7% on Better-Than-Expected Earnings

Flotek Industries (NYSE:FTK) saw its shares jump 29.7% after reporting significantly better-than-expected earnings and revenue. The oil and gas company posted an EPS of $0.26 against an estimated $0.13, and revenue of $99.37 million, far exceeding the $69.51 million forecast. Analyst sentiment remains positive, …

FTK main company
Sharemaestro market context Trend signal active 52 weeks +200.6% · Next-week setup negative 44.3% FTK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AMETEK Q2 Earnings Surpass Expectations, Revenues Rise Y/Y

AMETEK (AME) reported strong second-quarter 2026 results, with both earnings and revenues surpassing Zacks Consensus Estimates. The company saw a 17% increase in non-GAAP earnings per share year-over-year and a 15% rise in top-line revenues, driven by growth in its EIG and EMG segments. …

AME main company
Sharemaestro market context Trend signal active 52 weeks +37.1% · Next-week setup positive 55.4% AME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

RBC raises Ametek stock price target on strong Q2 results

RBC Capital has raised its price target for Ametek Inc. (NYSE:AME) to $291 from $260, maintaining an Outperform rating, following the company's strong second-quarter 2026 results. Ametek reported significant orders growth of 28% and organic sales growth of 10%, driven by strength in aerospace, …

AME main company
Sharemaestro market context Trend signal active 52 weeks +37.1% · Next-week setup positive 55.4% AME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

Teknova has launched Build-Tek™, an AI-powered custom order configurator for complex reagent requests, expanding on its 2024 buffer configurator. This tool allows therapeutic and diagnostic developers to design custom products and submit quote requests in minutes, significantly reducing the time from weeks to days. …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Teknova AI lets developers configure custom reagents in minutes

Teknova (Nasdaq: TKNO) has launched Build-Tek™, an AI-powered configurator that allows therapeutic and diagnostic developers to design complex custom reagents and submit quote requests in minutes. This system guides users through various specifications, significantly reducing the time for quote generation from weeks to two …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Roth Capital Initiates Alpha Teknova at Buy With $7 Price Target

Roth Capital has initiated coverage of Alpha Teknova (TKNO) with a Buy rating and set a price target of $7. This indicates a positive outlook from the investment bank on the company's future stock performance.

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Earnings To Watch: Alpha Teknova Inc (TKNO) Q2 2026 -- GF Value Sees 24% Downside

Alpha Teknova Inc (TKNO) is preparing to release its Q2 2026 earnings, with revenue expected to hit $10.97 million and earnings at $-0.08 per share. While analyst estimates show an average price target implying a significant upside, GuruFocus's GF Value suggests a 24% downside …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Segall Bryant & Hamill LLC Sells 61,742 Shares of Mitek Systems, Inc. $MITK

Segall Bryant & Hamill LLC has reduced its stake in Mitek Systems, Inc. by 34.6%, selling 61,742 shares and retaining 116,819 shares valued at approximately $1.58 million. Despite this sale, institutional investors collectively own a significant 83.64% of the company. Mitek Systems reported strong …

MITK main company
Sharemaestro market context Trend signal active 52 weeks +84.2% MITK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Roth/MKM initiates Alpha Teknova stock with buy rating on growth outlook

Roth/MKM has initiated coverage on Alpha Teknova Inc. (NASDAQ:TKNO) with a Buy rating and a $7.00 price target, citing the company's strong growth prospects and high customer retention. The firm highlighted Alpha Teknova's differentiated customizable solutions for the life sciences sector and the potential …

TKNO main company
Sharemaestro market context Trend signal active 52 weeks +53.5% TKNO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Flotek Industries, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:FTK) 2026-08-05

Flotek Industries reported a strong second quarter with record data analytics revenue, significant international chemistry sales, and increased profitability. The company's total revenue neared $100 million, marking its best quarterly performance in a decade, and net income rose substantially. Flotek also secured a 10-year, …

FTK main company
Sharemaestro market context Trend signal active 52 weeks +200.6% · Next-week setup negative 44.3% FTK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AMETEK Q2 2026 earnings: 15% sales growth supports higher guidance

AMETEK (NYSE: AME) reported strong Q2 2026 results with a 15% year-over-year revenue increase to $2.04 billion and a 17% rise in adjusted EPS to $2.09. The company's Electronic Instruments Group and Electromechanical Group both showed double-digit sales growth, and robust order growth led …

AME main company
Sharemaestro market context Trend signal active 52 weeks +37.1% · Next-week setup positive 55.4% AME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context